Changing Healthcare Worldwide

Advancing Pro-Anabolic science

In July of 2012, TDSC announced that they were in the later development stages of their first product, Testagen™, a spray-on treatment for low testosterone levels in men. Approximately, 13.8 million men in the United States suffer from low testosterone levels, commonly referred to as “Low T”, which has been linked to common ailments ranging from hypertension to low sex drive. Of the men suffering from low testosterone, it is estimated that only 1 million are currently undergoing treatment. Testosterone Replacement Therapy (TRT) drug sales have increased dramatically over the past decade, from approximately $552 million in 2006 to $2.1 billion in 2012. 

The safety and efficiency of transdermally delivered testosterone for hormone replacement has been extensively researched; however, there are product safety issues with all current forms of the specialized form of treatment, including site-of-application reactions in patches and roll-on gels, and dangers of inadvertent dosing to third parties by contact with gel preparations remaining on the skin. 

Testagen™ TDS has been under evaluation for over ten years and is designed to address these problems of transdermal hormone replacement therapies. The patented treatment formulation is expected to revolutionize topical testosterone application as the system provides faster absorption and lowers transferable concentrations left on the skin. To ensure the drug’s delivery is safe and as efficient as possible, the formulation process produces an extremely stable dose-specific and drug-specific formula, and has a quick-to-dry ethanol base that mitigates transference.